---
title: "Kailera Therapeutics, Inc. (KLRA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KLRA.US.md"
symbol: "KLRA.US"
name: "Kailera Therapeutics, Inc."
datetime: "2026-04-17T20:43:22.278Z"
locales:
  - [en](https://longbridge.com/en/quote/KLRA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KLRA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KLRA.US.md)
---

# Kailera Therapeutics, Inc. (KLRA.US)

## Company Overview

Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist.

| Item | Detail |
|------|--------|
| Exchange | US Market |
| Website | [www.kailera.com](https://www.kailera.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KLRA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KLRA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KLRA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KLRA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**